Hypertension and Stroke Prevention

  • J. D. Spence


The management of hypertension is now more effective than ever before, but even today there is a problem with recognition of the goal of therapy. Since hypertension is asymptomatic, its treatment cannot improve a person’s wellbeing; in fact, it may detract from it through the adverse effects of therapy. The goal of treatment is to prevent hypertensive vascular complications1,2; so it is necessary to understand the pathophysiologic mechanisms of these complications and their responses to treatment. Some effects of hypertension respond to lowering of blood pressure, while others are less responsive, 3–11 and both responses give insight into the way that vascular complications occur.


Antihypertensive Drug Cerebral Autoregulation Multiple Risk Factor Intervention Trial Hypertensive Encephalopathy Antiatherosclerotic Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pickering G. Hypertension, Causes, Consequences and Management. London: Churchill Livingstone; 1974: pp 40–62.Google Scholar
  2. 2.
    Kannel WB, Sorlie P. Hypertension in Framingham. In: Stratton PO ed. Epidemiology and Control of Hypertension. New York: Intercontinental Medical Books; 1975; p 553.Google Scholar
  3. 3.
    Samuelsson O, Wilhelmson L, Andersson O, et al. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. JAMA. 1988;258:1768–1776.CrossRefGoogle Scholar
  4. 4.
    Veterans Administration Trial on effects of antihypertensive treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970; 213:1143–1152.CrossRefGoogle Scholar
  5. 5.
    Beevers DG, Fairman MJ, Hamilton T, et al. Antihypertensive treatment and the course of established cerebral vascular disease. Lancet. 1973; 1:1407–1409.PubMedCrossRefGoogle Scholar
  6. 6.
    Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program: I. Reduction in mortality in persons with high blood pressure, including mild hypertension. JAMA. 1979; 242:2562–2571.CrossRefGoogle Scholar
  7. 7.
    Management Committee of the Australian Therapeutic Trial in Mild Hypertension. The Australian therapeutic trial in mild hypertension. Lancet. 1980; 1:1261–1267.Google Scholar
  8. 8.
    Morgan T, Adam W, Carney S, et al. Treatment of mild hypertension in elderly males. Clin Sci. 1979; 57:255s–357s.Google Scholar
  9. 9.
    Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: Risk factor changes and mortality results. JAMA. 1982; 248:1465–1477.CrossRefGoogle Scholar
  10. 10.
    Berglund G, Sannerstedt R, Andersson O, et al. Coronary heart disease after treatment of hypertension. Lancet. 1978;1:1–5PubMedCrossRefGoogle Scholar
  11. 11.
    Spence JD. Antihypertensive therapy and atherosclerosis. In: Rapaport E, ed. Cardiology Update. New York: Elsevier; 1986: pp 137–155.Google Scholar
  12. 12.
    Spence JD. Antihypertensive therapy and prevention of atherosclerotic stroke. Stroke. 1986;17:808–810.PubMedCrossRefGoogle Scholar
  13. 13.
    Birkett NJ, Donner A. Prevalence and control of hypertension in an Ontario county. Can Med Assoc J. 1985;132:1019–1024.PubMedGoogle Scholar
  14. 14.
    Russell RWR. How does high blood pressure cause stroke? Lancet. 1975;2:1283–1285.PubMedCrossRefGoogle Scholar
  15. 15.
    Giese J. Acute hypertensive vascular disease: 2. Studies on vascular reaction patterns and permeability changes by means of vital microscopy and colloidal tracer technique. Acta Path Microbiol Scand. 1964;62:497.PubMedGoogle Scholar
  16. 16.
    Skinhoj E, Strandgaard S. Pathogenesis of hypertensive encephalopathy. Lancet. 1973;1:461–462.PubMedCrossRefGoogle Scholar
  17. 17.
    Strandgaard S, Olesen J, Skinhoj E, et al. Autoregulation of brain circulation in severe arterial hypertension. Brit Med J. 1973;1:507–510.PubMedCrossRefGoogle Scholar
  18. 18.
    Folkow B. Structural factors: The vascular wall. Consequences of treatment. Hypertension. 1983; 5(suppl. III):58–62.Google Scholar
  19. 19.
    van Harten J, Burggraaf K, Danhof M, et al. Negligible sublingual absorption of nifedipine. Lancet. 1987; 2:1363–1365.PubMedCrossRefGoogle Scholar
  20. 20.
    Letter to the editor. Nifedipine, hypotension and myocardial injury. Ann Int Med. 1988;108:305–306.Google Scholar
  21. 21.
    Spence JD, Del Maestro RF. Hypertension in acute strokes: Treat. Arch Neurol. 1985;42:1000–1002.PubMedCrossRefGoogle Scholar
  22. 22.
    Hachinski VC, Norris JW. The vascular infrastructure. In: The Acute Stroke. Philadelphia: FA Davis; 1985: pp 27–40.Google Scholar
  23. 23.
    Gilbert JJ, Vinters HV. Cerebral amyloid angiopathy: Incidence and complications in the aging brain: I. Cerebral hemorrhage. Stroke. 1983;14:915–923.PubMedCrossRefGoogle Scholar
  24. 24.
    Vinters HV, Gilbert JJ. Cerebral amyloid angiopathy: incidence and complications in the aging brain: II. the distribution of amyloid vascular changes. Stroke. 1983;14:924–928.PubMedCrossRefGoogle Scholar
  25. 25.
    Fisher CM. Lacunar infarction. In: Toole JF, Sickert R, Whisnant J, eds. Cerebral Vascular Disease (Sixth Princeton Conference). New York, NY: Grune & Stratton; 1968: pp 232–236.Google Scholar
  26. 26.
    Hachinski VC, Potter P, Merskey H. Leuko-araiosis: an ancient term for a new problem. Can J Neurol Sci. 1986;13:533–534.PubMedGoogle Scholar
  27. 27.
    Floras JS. Antihypertensive treatment, myocardial infarction, and nocturnal myocardial ischemia. Lancet. 1988;2:994–996.PubMedCrossRefGoogle Scholar
  28. 28.
    Kaplan JR, Manuck SB, Adams MR, et al. The effects of beta-adrenergic blocking agents on atherosclerosis and its complications. Europ Heart J. 1987;8:928–944.Google Scholar
  29. 29.
    Schwartz CJ, Mitchell JRA. Observations on localization of arterial plaques. Circ Res. 1962; 11:63–73.PubMedGoogle Scholar
  30. 30.
    Glagov S, Zarins CK, Stankunavicius R, et al. Compensatory enlargement of human atherosclerotic coronary arteries. TV Engl J Med. 1987;316:1371–1375.CrossRefGoogle Scholar
  31. 31.
    Haust MD. Injury and repair in the pathogenesis of atherosclerotic lesions. In: Jones RJ, ed. Atherosclerosis. New York, NY: Springer Pub; 1970: pp 12–20.Google Scholar
  32. 32.
    Haust MD, More RH. Development of modern theories on the pathogenesis of atherosclerosis. In: Wissler RW, Geer JC, eds. The Pathogenesis of Atherosclerosis. Baltimore, MD: Williams and Wilkins; 1972: pp 1–19.Google Scholar
  33. 33.
    Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med. 1976;295:36–77.Google Scholar
  34. 34.
    Texon M. Hemodynamic Basis of Atherosclerosis. New York, NY: Hemisphere Publ Co; 1980.Google Scholar
  35. 35.
    Fry DL. Acute vascular endothelial changes associated with increased blood velocity gradients. Circ Res. 1968;22:165–167.PubMedCrossRefGoogle Scholar
  36. 36.
    Caro CG, Fitz-Gerald JM, Schroter RC. Atheroma and arterial wall shear; observation, correlation and proposal of a shear dependent mass transfer mechanism for atherogenesis. Proc Roy Soc Lond (Biol). 1971;107:109–124.CrossRefGoogle Scholar
  37. 37.
    Nerem RM, Cornhill JF. The role of fluid mechanics in atherogenesis. Biomech Eng. 1980;102:181–189.CrossRefGoogle Scholar
  38. 38.
    Milnor WR. Hemodynamics. Baltimore, MD: Williams and Wilkins; 1982.Google Scholar
  39. 39.
    Stein PD, Sabbah HN. Hemorrheology of turbulence. Biorrheology. 1980;17:301–309.Google Scholar
  40. 40.
    Burton AC. Kinetic energy in the circulation: Streamline flow and turbulence: measurement of arterial pressure. In: Physiology and Biophysics of the Circulation. Chicago, IL: Year Book Medical Publishers; 1972: pp 101–113.Google Scholar
  41. 41.
    Roach MR, Scott S, Ferguson CG The hemodynamic importance of the geometry of bifurcations in the circle of Willis (glass model studies). Stroke. 1972;3:255–267.PubMedCrossRefGoogle Scholar
  42. 42.
    Yellin EL. Laminar-turbulent transition process in pulsatile flow. Circ Res. 1966;19L:791–804.CrossRefGoogle Scholar
  43. 43.
    Spence JD. Spectral analysis of carotid vs femoral Doppler velocity patterns: a clue to the genesis of flow disturbances in cerebral arteries? In: Cohen, BA, ed. Frontiers of Engineering in Health Care; CH 1621, February 1981, 0000–0355-377. New York, NY: Institute for Electrical Engineering; 1981: pp 355–359.Google Scholar
  44. 44.
    Kannel WB, Kannel CE, Paffenbarger R. Heart rate and cardiovascular mortality in the Framingham study. Circulation. 1985;72 (suppl 3): 111–151.Google Scholar
  45. 45.
    Kaplan JR, Manuck SB, Clarkson TB. The influence of heart rate on coronary atherosclerosis. J Cardiovasc Pharm. 1987; 10 (suppl 2):S100–S102.Google Scholar
  46. 46.
    Friedman MH, Deters OJ, Bargeron CB, et al. Shear-dependent thickening of the human arterial intimax. Atherosclerosis. 1986;60:161–171.PubMedCrossRefGoogle Scholar
  47. 47.
    Friedman MH, O’Brien B, Ehrlich LW. Calculations of pulsatile flow through a branch: implications for the hemodynamics of atherosclerosis. Circ Res. 1975;36:277–285.PubMedCrossRefGoogle Scholar
  48. 48.
    Spence JD. Pathogenesis of atherosclerosis: effects of antihypertensive drugs. J Hum Exp Hyp. 1989; 3:63–68.Google Scholar
  49. 49.
    Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365–374.CrossRefGoogle Scholar
  50. 50.
    Spence JD, Pesout AB, Melmon KL. Effects of antihypertensive drugs on blood velocity in rhesus monkeys. Stroke. 1977;8:589–594.PubMedCrossRefGoogle Scholar
  51. 51.
    Spence JD. Effects of antihypertensive drugs on blood velocity: implications for atherogenesis. Can Med Assoc J. 1982;127:721–724.PubMedGoogle Scholar
  52. 52.
    Spence JD. Effects of hydralazine versus propranolol on blood velocity patterns in patients with atherosclerosis. Clin Sci. 1983;65:91–93.PubMedGoogle Scholar
  53. 53.
    Spence JD, Perkins DG, Kline RL, et al. Hemodynamic modification of aortic atherosclerosis: effects of propranolol vs hydralazine in hypertensive hyperlipidemic rabbits. Atherosclerosis. 1984;50: 325–333.PubMedCrossRefGoogle Scholar
  54. 54.
    Scanapieco G, Pauletto P, Semplicini A, et al. Evaluation of the efficacy of various hypotensive drugs in broad-breasted white turkeys as an experimental model of arterial hypertension with high catecholamine levels. Boll Soc Ital Biol Sper. 1983;59:1265–1271.Google Scholar
  55. 55.
    Kaplan J, Manuck SB, Adams MR, et al. Inhibition of coronary atherosclerosis by propranolol in behav-iourally predisposed monkeys fed an atherogenic diet. Circulation. 1987;76:1363–1372.CrossRefGoogle Scholar
  56. 56.
    Winther K, Trap-Jensen J. Effects of three beta-blockers with different pharmacodynamic properties on platelet aggregation and platelet and plasma cyclic AMP. Eur J Clin Pharm. 1988;35:17–20.CrossRefGoogle Scholar
  57. 57.
    Weinstein DB, Heider JG. Protective action of calcium channel antagonists in atherogenesis and experimental vascular injury. Am J Hypertension. 1989;2:205–212.Google Scholar
  58. 58.
    Fleckenstein A, Fleckenstein-Grun G, Frey M, et al. Calcium antagonism and ACE inhibition: two outstandingly effective means of interference with cardiovascular calcium overload, high blood pressure, and arteriosclerosis in spontaneously-hypertensive rats. Am J Hypertension. 1989;2:194–204.Google Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • J. D. Spence

There are no affiliations available

Personalised recommendations